ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma

NCT ID: NCT04634357

Last Updated: 2025-04-09

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-07-19
• Study Completion Date: 2028-01-31

Brief Summary

Open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety/tolerability and determine the recommended Phase II Dose (RP2D) of ET140203 T-cells in pediatric subjects who are AFP-positive/HLA-A2-positive and have relapsed/refractory HB, HCN-NOS, or HCC.

Detailed Description

The trial starts with a dose escalation phase. A traditional dose escalation model (3+3) design will be used to determine the recommended phase II dose (RP2D). Subjects will then be treated at the RP2D in the expansion phase of the trial.

Following treatment, tumor response assessments will be performed at Months 1, 3, 6, 9, 12, 18, and 24. At each tumor response assessment visit, imaging will be performed (triphasic CT Scan) and used for response evaluation. Serum AFP levels will also be measured at each tumor response assessment visit.

The active assessment phase of the study will continue for 2 years. Subjects will be followed for 15 years post-treatment for assessment of treatment safety and overall survival.

Conditions

Hepatoblastoma; Hepatocellular Carcinoma (HCC); Liver Neoplasms; Metastatic Liver Cancer; Liver Cancer; HEMNOS

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

ET140203 T Cells

ET140203 Autologous T Cells

Group Type: EXPERIMENTAL

ET140203 T Cells

Intervention Type: DRUG

Biological/Vaccine: ET140203 autologous T-cell product

Autologous T cells transduced with lentivirus encoding an ET140203 expression construct

Interventions

ET140203 T Cells

Biological/Vaccine: ET140203 autologous T-cell product

Autologous T cells transduced with lentivirus encoding an ET140203 expression construct

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Histologically confirmed HB, HCN-NOS, or HCC with serum AFP >100ng/mL at the time of screening and following the most recent line of therapy.

2. Disease reoccurrence after remission following initial standard-of care (SOC) treatment (i.e., relapse) or failure of response to SOC treatment (i.e., refractory).

3. Age ≥ 1 year and ≤ 21 years.

4. Molecular Human Leukocyte Antigen (HLA) class I allele typing that confirms subject carries at least one HLA-A2 allele.

5. Life expectancy of > 4 months per the Investigator's opinion.

6. Lansky or Karnofsky Performance Scale ≥ 70.

7. For enrollment to the dose-finding cohort, subjects must have at least one (1) lesion ≥ 5 mm in diameter or two (2) or more lesions ≥ 3 mm in diameter. For the dose-expansion cohort, subjects must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

8. Child-Pugh score of A6 or better.

9. Adequate organ function.

Exclusion Criteria

1. Recurrent HB who are candidates for complete surgical resection (e.g., isolated pulmonary relapse amendable to pulmonary metastasectomy).

2. Pre-existing illness including heart failure, uncontrolled pulmonary disease not cancer-related, or psychiatric illness/social situation that would limit compliance with study requirements.

3. Active, uncontrolled systemic bacterial, fungal, or viral infection. Subjects with Human Immunodeficiency Virus (HIV), hepatitis B, or hepatitis C are eligible provided their infection is being treated and the viral load is controlled.

4. Any known active malignancy (other than HB, HCN-NOS, or HCC).

5. Pregnant or lactating women.

6. Received the following within two (2) weeks of leukapheresis or within two (2) weeks of conditioning chemotherapy: cytotoxic chemotherapy, radiation, other anti-cancer therapies (including immunotherapeutic agents), immunosuppressive therapy, or systemic corticosteroids at doses greater than 5 mg/day of prednisone or equivalent doses of other corticosteroids. (Note: Topical and inhaled corticosteroids in standard doses and physiological replacement doses of corticosteroids for adrenal insufficiency are allowed).

7. Concurrently receiving other investigational agents, biological, chemical, or radiation therapies, while participating in the study.

8. Contraindication for receipt of conditioning chemotherapeutic agents including Fludarabine and Cyclophosphamide.

9. Active autoimmune disease requiring systemic immunosuppressive therapy.

10. Compromised circulation in the main portal vein, hepatic vein, or vena cava due to partial or complete obstruction which, in the opinion of the Investigator, would make the subject unsuitable for the study.

11. History of organ transplant.

12. HB, HCN-NOS, or HCC involving greater than 50% of the liver (volumetric).

• Minimum Eligible Age: 1 Year
• Maximum Eligible Age: 21 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Eureka Therapeutics Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Pei Wang, PhD

Role: STUDY_DIRECTOR

Eureka Therapeutics Inc.

Locations

UCSF Benioff Children's Hospitals

San Francisco, California, United States

Site Status: RECRUITING

Dana-Farber/Boston Children's Cancer and Blood Disorders Center

Boston, Massachusetts, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Teresa Klask, MBA

Role: CONTACT

Teresa.Klask@eurekainc.com

510-722-8719 ext. 412

Pei Wang, PhD

Role: CONTACT

Pei.Wang@eurekainc.com

510-654-7045

Facility Contacts

Karina Wong, CCRP

Role: primary

karina.wong@ucsf.edu

415-298-9434

Jill MacDonald

Role: primary

Jill_Macdonald@DFCI.Harvard.edu

617-632-4930

Other Identifiers

ETUS20AFPAR123

Identifier Type: -

Identifier Source: org_study_id